Research and Policy CSR News

4 Ways Johnson & Johnson Is Cultivating Outside-the-Box Innovations for COVID-19

By Jennifer Rainey Marquez
Summary: 

In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.

Article

In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.

Pink: More Than Just a Color

by Royce Epstein, A&D Design Director for Mohawk Group.
Multimedia with summary

The beautiful shades of pink are more than just colors.

Each October is Breast Cancer Awareness Month. It’s a time to remember to get a mammogram, educate yourself and your family about the risks of cancer, and also raise awareness and funds for breast cancer research and patient resources.

FedEx Express, iRAP Launch 5-star Global Connections Initiative in India

Article

The International Road Assessment Programme (iRAP), a registered charity dedicated to preventing road deaths through safer road infrastructure, in association with FedEx Express, the express transportation company and a subsidiary of FedEx Corp., has announced the launch of the 5-Star Global Connections Initiative. The programme will unlock the power of partnerships across India and share success across more than 100 countries who have their own RAP programme and project activity.

Leading HSE In The Ongoing Crisis Response

Article

Mohawk Goes Pink: Doing Our Part For a Cure

Multimedia with summary

Since 2001, Mohawk Industries has contributed more than $6 million to Susan G. Komen, the largest breast cancer research organization in the United States. Through corporate donation programs including Decorate for the Cure and Specify for a Cure — as well as different employee-led initiatives — we are committed to this ongoing partnership to one day find a cure.

Understanding Health and Safety Impacts of the Pandemic

Training now available on occupational health and safety reporting
Press Release

October 7, 2020 /3BL Media/ - A new course has launched that helps companies to effectively incorporate occupational health and safety (OHS) impacts within their sustainability report – including insights on the OHS implications of the COVID-19 pandemic.

Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19

Summary: 

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Article

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

The Science & Art of Goal Setting: Announcing Johnson & Johnson's New Climate Goals

by Paulette Frank, Worldwide Vice President, Environmental Health, Safety & Sustainability at Johnson & Johnson
Blog

I am so incredibly proud to have had the privilege to share Johnson & Johnson’s new climate goals during this Climate Week NYC 2020.

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release

NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

Pages

Subscribe to Research and Policy